The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice
Open accessAbstract
Background and Aims: Cholestatic liver disease is characterized by gut dysbiosis and excessive toxic hepatic bile acids (BAs). Modification of gut microbiota and repression of BA synthesis are potential strategies for the treatment of cholestatic liver disease. The purpose of this study was to examine the effects and to understand the mechanisms of the probiotic Lactobacillus rhamnosus GG (LGG) on hepatic BA synthesis, liver injury, and fibrosis in bile duct ligation (BDL) and multidrug resistance protein 2 knockout ( Mdr2−/− ) mice. Approach and Results: Global and intestine‐specific farnesoid X receptor (FXR) inhibitors were used to dissect the role of FXR. LGG treatment significantly attenuated liver inflammation, injury, and fibrosis with a significant reduction of hepatic BAs in BDL mice. Hepatic concentration of taurine‐β‐muricholic acid (T‐βMCA), an FXR antagonist, was markedly increased in BDL mice and reduced in LGG‐treated mice, while chenodeoxycholic acid, an FXR agonist, was decreased in BDL mice and normalized in LGG‐treated mice. LGG treatment significantly increased the expression of serum and ileum fibroblast growth factor 15 (FGF‐15) and subsequently reduced hepatic cholesterol 7α‐hydroxylase and BA synthesis in BDL and Mdr2−/− mice. At the molecular level, these changes were reversed by global and intestine‐specific FXR inhibitors in BDL mice. In addition, LGG treatment altered gut microbiota, which was associated with increased BA deconjugation and increased fecal and urine BA excretion in both BDL and Mdr2−/− mice. In vitro studies showed that LGG suppressed the inhibitory effect of T‐βMCA on FXR and FGF‐19 expression in Caco‐2 cells. Conclusion: LGG supplementation decreases hepatic BA by increasing intestinal FXR–FGF‐15 signaling pathway–mediated suppression of BA de novo synthesis and enhances BA excretion, which prevents excessive BA‐induced liver injury and fibrosis in mice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Bile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Targeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422 · cited 1×
“Secreted FGF-15 binds to FGF receptor/β-Klotho complex on hepatocytes and represses BA synthesis.(14) In sham mice, we observed a strong expression of FGF-15 protein.”
BackgroundBile Salt Hydrolase Activity in Probiotics
Begley, M., Hill, C., & Gahan, C. G. M. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.72.3.1729-1738.2006 · Cited by 1,187
Jones, B. V., Begley, M., Hill, C., Gahan, C. G. M., & Marchesi, J. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804437105 · Cited by 1,098
Carey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Bile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559
Self-citationA Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
Urizar, N. L., Liverman, A. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002) · Science · doi:10.1126/science.1072891 · Cited by 549
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
Kong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456
Song, K., Li, T., Owsley, E., Strom, S., & Chiang, J. Y. L. (2009) · Hepatology · doi:10.1002/hep.22627 · Cited by 414
Liu, Y., Binz, J., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18945 · Cited by 398
Self-citationBile acid transporters and regulatory nuclear receptors in the liver and beyond
Halilbasic, E., Claudel, T., & Trauner, M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.08.002 · Cited by 393
Degirolamo, C., Rainaldi, S., Bovenga, F., Murzilli, S., & Moschetta, A. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.032 · Cited by 356
Cyp2c70 is responsible for the species difference in bile acid metabolism between mice and humans
Takahashi, S., Fukami, T., Masuo, Y., Brocker, C. N., Xie, C., Krausz, K. W., Wolf, C. R., Henderson, C. J., & Gonzalez, F. J. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m071183 · Cited by 313
Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas
Miyoshi, H., Rust, C., Roberts, P. J., Burgart, L. J., & Gores, G. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70461-0 · Cited by 311
The ascending pathophysiology of cholestatic liver disease
Jansen, P. L. M., Ghallab, A., Vartak, N., Reif, R., Schaap, F. G., Hampe, J., & Hengstler, J. G. (2017) · Hepatology · doi:10.1002/hep.28965 · Cited by 301
Mutations in the nuclear bile acid receptor FXR cause progressive familial intrahepatic cholestasis
Gomez-Ospina, N., Potter, C. J., Xiao, R., Manickam, K., Kim, M.-S., Kim, K. H., Shneider, B. L., Picarsic, J. L., Jacobson, T. A., Zhang, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms10713 · Cited by 300
Hartmann, P., Hochrath, K., Horvath, A., Chen, P., Seebauer, C. T., Llorente, C., Wang, L., Alnouti, Y., Fouts, D. E., Stärkel, P., et al. (2018) · Hepatology · doi:10.1002/hep.29676 · Cited by 290 · cited 1×
“Changes in BA signatures as well as modulation of the enterohepatic FXR/FGF-15/CYP7A1 axis were found in germ-free, gnotobiotic, and antibiotic-treated animals.(36) Bacterial metabolism– mediated primary BA deconjugation and subsequent conversion determine the amount of secondary BAs that might be detrimental to intes…”
BackgroundSchaap, F. G., van der Gaag, N. A., Gouma, D. J., & Jansen, P. L. M. (2009) · Hepatology · doi:10.1002/hep.22771 · Cited by 284
Modica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275
Bajaj, J. S., Heuman, D. M., Hylemon, P. B., Sanyal, A. J., Puri, P., Sterling, R. K., Luketic, V., Stravitz, R. T., Siddiqui, M. S., Fuchs, M., et al. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12695 · Cited by 274
The gut microbiota drives the impact of bile acids and fat source in diet on mouse metabolism
Just, S., Mondot, S., Ecker, J., Wegner, K., Rath, E., Gau, L., Streidl, T., Hery-Arnaud, G., Schmidt, S., Lesker, T. R., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0510-8 · Cited by 269
Pathak, P., Liu, H., Boehme, S., Xie, C., Krausz, K. W., Gonzalez, F., & Chiang, J. Y. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.784322 · Cited by 253
Structures of β-klotho reveal a ‘zip code’-like mechanism for endocrine FGF signalling
Lee, S., Choi, J., Mohanty, J., Sousa, L. P., Tome, F., Pardon, E., Steyaert, J., Lemmon, M. A., Lax, I., & Schlessinger, J. (2018) · Nature · doi:10.1038/nature25010 · Cited by 236
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
Biliary bile acids in hepatobiliary injury – What is the link?
Fickert, P., & Wagner, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.026 · Cited by 185
Wang, Y., Liu, Y., Kirpich, I., Ma, Z., Wang, C., Zhang, M., Suttles, J., McClain, C., & Feng, W. (2013) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2013.02.001 · Cited by 171
Self-citationMantegazza, C., Molinari, P., D’Auria, E., Sonnino, M., Morelli, L., & Zuccotti, G. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.08.001 · Cited by 152
Frankenberg, T., Miloh, T., Chen, F. Y., Ananthanarayanan, M., Sun, A., Balasubramaniyan, N., Arias, I. M., Setchell, K. D. R., Suchy, F. J., & Shneider, B. L. (2008) · Hepatology · doi:10.1002/hep.22431 · Cited by 125
Crosstalk between Bile Acids and Gut Microbiota and Its Impact on Farnesoid X Receptor Signalling
Wahlstrom, A. M., Kovatcheva‐Datchary, P., Ståhlman, M., Bäckhed, F., & Marschall, H. (2017) · Digestive Diseases · doi:10.1159/000450982 · Cited by 119
Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice
Zollner, G., Fickert, P., Silbert, D., Fuchsbichler, A., Stumptner, C., Zatloukal, K., Denk, H., & Trauner, M. A. (2002) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00215.2001 · Cited by 77
Fuchs, C. D., Paumgartner, G., Mlitz, V., Kunczer, V., Halilbasic, E., Leditznig, N., Wahlström, A., Ståhlman, M., Thüringer, A., Kashofer, K., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314553 · Cited by 76
Orso, G., Mandato, C., Veropalumbo, C., Cecchi, N., Garzi, A., & Vajro, P. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2015.11.003 · Cited by 64
Bacterial bile salt hydrolase: an intestinal microbiome target for enhanced animal health
Geng, W., & Lin, J. (2016) · Animal Health Research Reviews · doi:10.1017/s1466252316000153 · Cited by 61
SRT1720 Alleviates ANIT-Induced Cholestasis in a Mouse Model
Yu, L., Liu, X., Yuan, Z., Li, X., Yang, H., Yuan, Z., Sun, L., Zhang, L., & Jiang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00256 · Cited by 55
Self-citationZhang, C., Xu, Y., Xiang, D., Yang, J., Lei, K., & Liu, D. (2018) · Current Medical Science · doi:10.1007/s11596-018-1861-x · Cited by 22
Cited by
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Molecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
Gut microbiome, liver immunology, and liver diseases
Wang, R., Tang, R., Li, B., Ma, X., Schnabl, B., & Tilg, H. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00592-6 · Cited by 466
Targeting gut microbiota and metabolism as the major probiotic mechanism - An evidence-based review
Ma, T., Shen, X., Shi, X., Sakandar, H. A., Quan, K., Li, Y., Jin, H., Kwok, L.-Y., Zhang, H., & Sun, Z. (2023) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2023.06.013 · Cited by 329
Promises of microbiome-based therapies
Bajaj, J. S., Ng, S. C., & Schnabl, B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.003 · Cited by 119
Metadata
- Authors
- Liu, Y., Chen, K., Li, F., Gu, Z., Liu, Q., He, L., Shao, T., Song, Q., Zhu, F., Zhang, L., Jiang, M., Zhou, Y., Barve, S., Zhang, X., McClain, C. J., & Feng, W.
- Venue
- Hepatology
- Published
- 2020-03-16
- Volume
- 71
- Issue
- 6
- Pages
- 2050-2066
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2978988403
- Cited by
- 364
- References
- 40
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.